Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Vanita Noronha, MBBS, MD, DM, of the Tata Memorial Center, Mumbai, India, discusses the results of a Phase III study investigating gefitinib versus combination therapy in the treatment of non-small cell lung cancer (NSCLC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.